timothy sykes logo
CDNA Surges As CareDx Hikes 2026 Revenue Guidance Thumbnail
G Google News

CDNA Surges As CareDx Hikes 2026 Revenue Guidance

ELLIS HOBBS•UPDATED AUG. 2, 2026, 11:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

CareDx Inc. stocks have been trading up by 12.84 percent, driven primarily by strong transplant diagnostics progress and upbeat outlook.

What Traders Need To Know

  • Q2 2026 revenue jumped to $132M, up 52% year over year, powered by 61% growth in testing services and higher revenue per test at $1,720.
  • GAAP profitability was aided by a $113M gain on the Lab Products divestiture, while non-GAAP net income reached $20M and adjusted EBITDA hit $25M.
  • Q2 non-GAAP EPS of $0.37 beat the $0.23 consensus, with revenue of $131.9M topping roughly $114M expectations.
  • Management lifted 2026 revenue guidance to $490–$500M and adjusted EBITDA to $66–$78M, well above prior ranges and Street estimates.
  • Shares of CareDx Inc. jumped roughly 14–15% on heavy volume after the Q2 beat and guidance hike, as traders embraced its precision diagnostics growth story.

Candlestick Chart

Weekly Update Jul 27 – Jul 31, 2026: On Sunday, August 02, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 12.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

CareDx now occupies a stronger niche position in transplant and precision diagnostics, with Q2 revenue of ~$132M and trailing revenue ~$380M growing low‑to‑mid teens annually pre-spike, and gross margin of 78% supporting an attractive model. EBIT margin above 20% and current ratio 4.6 highlight operating leverage and balance-sheet strength, while debt/equity of ~0.03 and robust interest coverage derisk the capital structure. Cash of ~$374M and consistently positive operating cash flow materially enhance strategic optionality.

Technically, the stock has broken out violently from the mid‑$30s, spiking intraday to $46.71 before settling just below $43, on very heavy volume around the earnings print. The dominant trend is now firmly bullish on the weekly timeframe, with a clear momentum gap between $38–$42. A logical tactical level is $38 as first major support; an aggressive long setup is buying near $38–$40 with a stop below $36 and targeting a retest of $46–$47.

Fundamentally, CareDx is now outperforming the broader Healthcare and Medical Diagnostics & Screening cohorts on revenue growth, margin trajectory, and guidance revision magnitude. The divestiture‑driven GAAP profit masks a genuine inflection to durable non‑GAAP profitability and positive FCF, supported by CMS coverage, Naveris integration, and higher‑value test mix. With Street estimates likely to reset higher, I see the stock re‑rating toward a 6.5–7x FY26 sales range, supporting a decisive 12‑month target of $50, with support ~$38 and resistance ~$47.

More Breaking News

Quick Financial Overview

CareDx Inc. delivered a breakout Q2 2026, with revenue surging to about $132M and strong 52% year-on-year growth. Testing services climbed 61%, and a $1,720 average revenue per test points to solid pricing power in transplant diagnostics. The company also shifted to GAAP profitability, helped by a $113M gain from selling its Lab Products business, while non-GAAP net income of $20M and adjusted EBITDA of $25M show the core operations are improving.

From a valuation and quality angle, CDNA sits on high-margin economics, with gross margin around 78.2% and EBIT margin at 22.9%. Revenue over the last few years has grown in the low-teens percentage annually, and the latest quarter suggests that pace is accelerating. Balance sheet strength stands out: a current ratio of 4.6, total debt-to-equity of just 0.03, and over $373M in cash support flexibility for further execution in precision molecular diagnostics.

On the tape, the weekly chart around late July 2026 shows CDNA breaking from the mid-$30s to a spike high near $46.71 on 2026/07/30, then settling just under $43 by 2026/07/31. That move lines up with the 14–15% post-earnings jump noted in the news. Intraday, the 5-minute snapshot shows a wide range between roughly $40.67 and $45, with a close around $43.71, signaling active two-way trade but control tilting to buyers. For short-term traders, that kind of expansion in range and volume usually marks a new, tradeable volatility regime.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”